BACE2 degradation is mediated by both the proteasome and lysosome pathways

Kaixin Qiu 1,2,3†, Wenping Liang 4,5†, Shuai Wang 2,3, Tingting Kong 1, Xin Wang 2,7, Chunyan Li 1,2,3, Zhe Wang 4,5 and Yili Wu 2,3*

Abstract

Background: Alzheimer’s disease is the most common neurodegenerative disease in the elderly. Amyloid-β protein (Aβ) is the major component of neuritic plaques which are the hallmark of AD pathology. β-site APP cleaving enzyme 1 (BACE1) is the major β-secretase contributing to Aβ generation. β-site APP-cleaving enzyme 2 (BACE2), the homolog of BACE1, might play a complex role in the pathogenesis of Alzheimer’s disease as it is not only a θ-secretase but also a conditional β-secretase. Dysregulation of BACE2 is observed in Alzheimer’s disease. However, the regulation of BACE2 is less studied compared with BACE1, including its degradation pathways. In this study, we investigated the turnover rates and degradation pathways of BACE2 in both neuronal cells and non-neuronal cells.

Results: Both lysosomal inhibition and proteasomal inhibition cause a time- and dose-dependent increase of transiently overexpressed BACE2 in HEK293 cells. The half-life of transiently overexpressed BACE2 protein is approximately 6 h. Moreover, the half-life of endogenous BACE2 protein is approximately 4 h in both HEK293 cells and mouse primary cortical neurons. Furthermore, both lysosomal inhibition and proteasomal inhibition markedly increases endogenous BACE2 in HEK293 cells and mouse primary cortical neurons.

Conclusions: This study demonstrates that BACE2 is degraded by both the proteasome and lysosome pathways in both neuronal and non-neuronal cells at endogenous level and in transient overexpression system. It indicates that BACE2 dysregulation might be mediated by the proteasomal and lysosomal impairment in Alzheimer’s disease. This study advances our understanding of the regulation of BACE2 and provides a potential mechanism of its dysregulation in Alzheimer’s disease.

Keywords: BACE2; half-life, Proteasome pathway: lysosome pathway
**Background**

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly. Amyloid-β protein (Aβ) is the major component of neuritic plaques which are the hallmark of AD pathology [1]. Deposition of Aβ is formed from amyloid-β precursor protein (APP) by sequential cleavage of β- and γ-secretase [2]. β-site APP cleaving enzyme 1 (BACE1) is the major β-secretase contributing to Aβ generation. β-site APP-cleaving enzyme 2 (BACE2), the homolog of BACE1, is a β-secretase, which cleaves APP at Phe20 site to yield a CTF with 80 amino acids (CTFθ or C80) contributing to the generation of a truncated Aβ [3, 4]. Moreover, BACE2 prevents neuronal apoptosis by cleaving a potassium channel at the surface of plasma membrane [5]. However, our recent study demonstrated that BACE2 can be converted into a β-secretase with comparable β-secretase activity to that of BACE1, implying that BACE2 could contribute to Aβ generation in AD [6]. Consistently, increased BACE2 expression and activity is detected in neurons of AD brains [7]. Genetic data highly supports that BACE2 is associated with AD risk. For example, BACE2 haplotype associates with AD, while SNPs in BACE2 (e.g., rs2252576, rs2837990, rs7281733) predispose to early onset of AD in patients with Down syndrome [8, 9]. Recently, the association between a number of SNPs in BACE2 and AD was detected in APOE ε4 non-carriers, which might be mediated by altered BACE2 expression-mediated Aβ generation and clearance [10]. It indicates that dysregulation of BACE2 might contribute to the pathogenesis of AD.

It is important to elucidate the regulation of BACE2 expression as BACE2 homeostasis is critical to maintain the physiological function and counteract the pathogenesis of AD. In addition to the transcriptional regulation, protein degradation does play an important role in BACE2 homeostasis [11]. The ubiquitin-proteasome pathway (UPS) and the autophagy-lysosome pathway (ALP) are two major pathways for protein degradation in eukaryotic cells [12, 13]. The impairment of the proteasome and lysosome activity in AD has been reported in a number of studies, which might contribute to the dysregulation of BACE2 in AD [14]. However, the degradation of BACE2 remains elusive. To further elucidate the feature of BACE2 degradation, we investigated BACE2 degradation in both neuronal and non-neuronal cells. We found that both lysosomal inhibition and proteasomal inhibition cause the increase of transiently overexpressed BACE2 in HEK293 cells. Moreover, both lysosomal inhibition and proteasomal inhibition markedly increases endogenous BACE2 levels in HEK293 cells and mouse primary cortical neurons, indicating that BACE2 is degraded by both the proteasome pathway and lysosome pathway. This work advances our understanding of the regulation of BACE2 and provides a potential mechanism of its dysregulation in AD. It might provide a potential strategy for the treatment of AD by targeting the dysregulation of BACE2 in AD.

**Results**

The half-life of transiently overexpressed BACE2 is approximately 6 h in HEK293 cells

Cycloheximide (CHX), also called actidione, was produced from Streptomyces griseus as a protein synthesis inhibitor [15]. To examine the half-life of BACE2, HEK293 cells were transfected with plasmid pBACE2-mycHis. 24 h after transfection, cells were divided equally into six dishes. 48 h after transfection, the cells were treated with 100 μg/mL CHX to block BACE2 synthesis [16–18]. The cells were harvested at 0, 2, 4, 8, 12 and 16 h time-point, respectively. Western blot analysis was performed to measure the level of remaining BACE2 protein relative to the BACE2 level at 0 h time-point. BACE2 protein levels were decreased to 63 ± 6.6%, 58 ± 7.6%, 45 ± 6.7%, 37 ± 4.6% and 32 ± 4.7% at 2, 4, 8, 12 and 16 h time-point, respectively, p < 0.05 (Fig. 1a and b). Our data showed that the half-life of transiently overexpressed BACE2 is approximately 6 h.

Lysosomal inhibition causes a time- and dose-dependent increase of transiently overexpressed BACE2 in HEK293 cells

To explore whether the lysosome pathway is implicated in BACE2 degradation, transfected HEK293 cells were treated with 0, 10, 25, or 50 mM of the lysosomal inhibitor NH4CL for 24 h. Western blot analysis showed that NH4CL treatment significantly increased BACE2 levels to 1.35 ± 0.09, 2.00 ± 0.12 and 2.40 ± 0.12 fold, respectively, compared to that of control cells, p < 0.05 (Fig. 2a and b). For the time course assay, BACE2 were treated with 25 mM NH4CL for 0, 6, 12 and 24 h, respectively. The levels of BACE2 were significantly increased to 1.28 ± 0.04, 1.79 ± 0.12 and 2.60 ± 0.19 fold, respectively, p < 0.05 (Fig. 2c and d).

Fig. 1 The half-life of transiently overexpressed BACE2 is approximately 6 h in HEK293 cells. a HEK293 cells were transfected with pBACE2-mycHis. 48 h after transfection, cells were treated with 100 μg/mL CHX for 0, 2, 4, 8, 12 and 16 h, respectively. Cell lysates were resolved by 10% SDS-PAGE. BACE2 expression was detected by using 9E10. β-actin was detected by AC-15 and served as an internal reference. b Quantification of BACE2 levels at each time-point. BACE2 protein levels were plotted as a percentage of the amount of BACE2 level at 0 h. Values are mean ± SEM; n ≥ 3
To further confirm the effect of lysosomal inhibition on BACE2 degradation, Bafilomycin A1 (Baf-A1), an inhibitor of autophagosome-lysosome fusion, was applied to BACE2 transfected cells at 0, 10, 100 and 300 nM for 24 h, respectively. Baf-A1 treatment significantly increased BACE2 levels to 1.49 ± 0.06, 1.97 ± 0.14 and 2.70 ± 0.06 fold, respectively, compared to that of control cells, \( p < 0.05 \) (Fig. 2e and f). For the time course assay, cells were treated with 100 nM Baf-A1 for 0, 4, 12 and 24 h. The levels of BACE2 were significantly increased to 1.65 ± 0.07, 2.79 ± 0.06 and 3.60 ± 0.19 fold, respectively, \( p < 0.05 \) (Fig. 2g and h). Our data showed that lysosomal inhibition causes a time- and dose-dependent increase of BACE2 expression, indicating that transiently overexpressed BACE2 is degraded by the lysosome pathway in HEK293 cells.

Proteasomal inhibition increases transiently overexpressed BACE2 in HEK293 cells

To explore whether the proteasome pathway is involved in BACE2 degradation, equal amount of pBACE2-mycHis transfected cells were treated with proteasomal inhibitor MG-132 at the concentration of 0, 10, 15 or 20 \( \mu \)M for 12 h. BACE2 levels were significantly increased to 6.87 ± 0.26, 7.14 ± 0.14 and 6.95 ± 0.20 fold at the dose of 10, 15 and 20 \( \mu \)M, compared to that in control cells, \( p < 0.05 \) (Fig. 3a and b). For the time course assay, cells were treated with 10 \( \mu \)M MG-132 for 0, 6, 12 and 24 h. BACE2 levels were significantly increased to 2.69 ± 0.20, 4.72 ± 0.32 and 6.46 ± 0.25 fold, respectively, compared to that in control cells, \( p < 0.05 \) (Fig. 3c and d). Our data showed that proteasomal inhibition causes a time- and dose-dependent increase of BACE2 expression, indicating that transiently overexpressed BACE2 is degraded by the proteasome pathway in HEK293 cells.

To further confirm the effect of proteasomal inhibition on BACE2 degradation, the proteasomal inhibitor ALLN was also applied to BACE2 transfected cells for 12 h. ALLN treatment significantly increased BACE2 levels to 5.107 ± 0.93, 4.78 ± 0.44 and 5.76 ± 0.71 fold at the dose of 5, 10 or 25 \( \mu \)M, respectively, compared to that in control cells, \( p < 0.05 \) (Fig. 3e and f). For the time course assay, cells were treated with 10 \( \mu \)M ALLN for 0, 6, 12 and 24 h. BACE2 levels were significantly increased to 2.69 ± 0.20, 4.72 ± 0.32 and 6.46 ± 0.25 fold, respectively, compared to that in control cells, \( p < 0.05 \) (Fig. 3g and h). It indicated that transiently overexpressed BACE2 is degraded by the proteosome pathway in HEK293 cells.

The half-life of endogenous BACE2 is approximately 4 h in HEK293 cells

To examine the half-life of endogenous BACE2, HEK293 cells were divided equally into four dishes. The cells were treated with 100 \( \mu \)g/mL CHX to block BACE2 synthesis [16–18]. Western blot analysis was performed to measure the level of remaining BACE2 protein relative to the BACE2 level at 0 h time-point. BACE2 protein levels were decreased to 41 ± 7.0%, 35 ± 4.6% and 24 ± 2.9% at 4, 8 and 12 h time-point, respectively, \( p < 0.05 \) (Fig. 4a and b). Our data showed that the half-life of endogenous BACE2 is approximately 4 h in HEK293 cells.

Both lysosomal inhibition and proteasomal inhibition increases the expression of endogenous BACE2 in HEK293 cells

HEK293 cells were divided equally into 6 cm dishes and treated with 10 \( \mu \)M MG-132 for 12 h and 25 mM NH\(_4\)CL for 24 h, respectively. Endogenous BACE2 levels...
were significantly increased to 3.21 ± 0.10 and 6.65 ± 0.20 fold by MG-132 and NH4CL treatments, respectively, compared to that in control cells, p < 0.05 (Fig. 5a and b). Our data demonstrated that endogenous BACE2 is degraded by both the lysosome pathway and the proteasome pathway in HEK293 cells.

The half-life of endogenous BACE2 is approximately 4 h in primary neurons

To examine the half-life of endogenous BACE2 in primary neurons, mouse primary cortical neurons were isolated and seeded equally into five dishes. 7 days later, the cells were treated with 100 μg/mL CHX to block BACE2 synthesis [16–18]. The cells were harvested at 0, 2, 4, 8 and 12 h time-point, respectively. Western blot analysis was performed to measure the level of remaining BACE2 protein relative to the BACE2 level at 0 h time-point. BACE2 protein levels were decreased to 62 ± 2.9%, 45 ± 2.3%, 34 ± 9.6% and 28 ± 4.4% at 2, 4, 8 and 12 h time-point, respectively, p < 0.05 (Fig. 6a and b). Our data showed that the half-life of endogenous BACE2 is approximately 4 h in primary neurons.

Both lysosomal inhibition and proteasomal inhibition increases the expression of endogenous BACE2 in primary neurons

The mouse primary cortical neurons were isolated and equally seeded. 7 days later, the primary neurons were treated with 100 μg/ml CHL and 5 μM MG132, respectively. Endogenous BACE2 levels were significantly increased to 3.97 ± 0.21 and 8.09 ± 0.90 fold by MG-132
BACE2 is only degraded by the autophagy-lysosome pathways [3, 19]. However, our previous study showed that degraded by both the proteasome and lysosome pathways are implicated in the degradation of BACE2. The different conclusion drawn from the current study and the previous study might be caused by the following reasons. First, the clonal effect of stable cells might contribute to the difference as it might not represent the features of BACE2 in the population of cells. In addition, the high expression level and long-term overexpression might cause stronger stress on the cells in stable overexpression system. Moreover, long-term overexpression of BACE2 might have global effect on gene transcription including genes involved in protein degradation system, which inversely affects BACE2 degradation. For example, our previous study did show that long-term overexpression of transmembrane protein APP reduces proteasome activity by downregulating the expression of core subunits of the proteasome complex [20]. Furthermore, long-term protein overexpression might exhaust the capacity of the proteasome degradation system, resulting in proteasome impairment, thus, the proteasomal inhibitor has no effect on the proteasome-mediated BACE2 degradation in stable cells.

Our previous study showed that the half-life of stably overexpressed BACE2 is around 20 h [18]. In the current study, we showed that the half-life of transient overexpressed BACE2 is approximately 6 h, while the half-life of endogenous BACE2 is approximately 4 h. The dramatic difference between the half-life of stably overexpressed BACE2 and the half-life of transiently overexpressed BACE2 or endogenous BACE2 might be caused by the following reasons. First, the clonal effect of stable cells might contribute to the difference as it might not represent the features of BACE2 in the population of cells. Moreover, the relative long half-life of BACE2 in stable cells might be attribute to the impairment of proteasome pathway or the reduced proteasome activity as described above.

Conclusions
In conclusion, we found that BACE2 is degraded by both the proteasome and the lysosome pathways in both neuronal cells and non-neuronal cells at endogenous level or in transient overexpression system, indicating that BACE2 degradation by both the proteasome and lysosome pathways is a common feature of BACE2. Moreover, the impairment of the proteasome pathway and the lysosome pathway in AD might lead to BACE2 dysregulation in neurons, contributing to the pathogenesis of AD [10]. This study not only advances our
understanding of the regulation of BACE2 but also provides a potential mechanism of its dysregulation in AD. Moreover, it might provide a strategy for the treatment of AD by targeting the dysregulation of BACE2.

Methods

Cell culture and transfection

Human embryonic kidney HEK293 cells obtained from Dr. Weihong Song’s lab were cultured in high-glucose DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. C57BL/6 mice were obtained from Cyagen Bioscience. Mouse cortical neurons were prepared from E18 embryos as described previously [6]. Briefly, the cortices of embryos were dissected out and the meninges were completely removed. The cortices were digested with papain at 37 °C for 20 min. Then, the papain solution was replaced with inactivation solution (MEM containing 0.6% D- [+] -glucose, 1 mM pyruvate, 10% horse serum, 2.5% bovine serum albumin [BSA], and 2.5% trypsin inhibitor) and the cells were dissociated by repeatedly pipetting. The isolated cells were equally seeded on poly-D-lysine–coated dishes with Neurobasal Media (Invitrogen) containing B27 [6]. All cells were maintained at 37 °C with 5% CO2 in an incubator as described previously [16, 18, 21]. The proteins expression was quantified by using ImageJ.

Pharmacological treatment

HEK293 cells were transiently transfected with pBACE2-mycHis. 24 h after transfection, the cells were equally seeded into 6 cm culture dishes. 48 h after transfection, the cells were treated with different drugs, respectively. To measure the half-life of BACE2, 100 μg/mL cycloheximide (CHX) was used to treat cells as described previously [16, 18, 21]. After treatment, the cells were harvested at 0, 2, 4, 8, 12 and 16 h time-point, respectively. Lysosomal inhibitor NH4Cl, Bafilomycin A1(Baf-A1) and chloroquine (CHL) were applied to determine the involvement of lysosome pathway in BACE2 degradation, while proteasomal inhibitors N-carbobenzoxy-L-leucinyl-L-leucinyl-L-leucinal (MG-132) and N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) were applied to determine the involvement of proteasome pathway in BACE2 degradation, respectively [16–18, 25, 26]. CHX, CHL and MG-132 were added to the primary cortical neurons at DIV7. MG-132, ALLN, NH4Cl, CHL, Baf-A1 and CHX were purchased from Sigma.

Western blotting

Cells were lysed with RIPA-Doc buffer (Tris-HCl 50 mM; NaCl, 150 mM; Triton X-100, 1%; deoxocholate, 1%; and SDS, 0.1%; supplemented with 1/100 protease inhibitors). Cell lysates were separated by 10% Tris-glycine SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked in 5% non-fat milk for 1 h, then incubated overnight at 4 °C with anti-myc (9E10), anti-BACE2 and anti-β-actin (AC-15) antibodies, respectively [18]. The membranes were washed in TBST with 0.1% Tween-20 and incubated with HRP-labeled goat anti-mouse or HRP-labelled goat anti-rabbit antibodies at room temperature for 1 h. Anti-myc antibody 9E10 was obtained from Abcam. Anti-BACE2 antibody was purchased from Santa Cruz (sc-271,212). β-actin antibody AC-15, HRP-labelled goat anti-rabbit antibody and HRP-labelled goat anti-mouse antibody were obtained from ZSGB-BIO. The image was obtained by using FluorChem R imaging system.

Statistical analysis

The proteins expression was quantified by using ImageJ. One-way ANOVA followed by Tukey’s test was used for data analysis with three or more independent experiments. P < 0.05 was considered as a significant difference.

Abbreviations

Aβ: Amyloid-β protein; AD: Alzheimer’s Disease; APP: Amyloid-β precursor protein; BACE1: β-site APP cleaving enzyme 1; BACE2: β-site APP cleaving enzyme 2

Acknowledgements

We thank Dr. Weihong Song for providing some reagents.

Authors’ contributions

YW conceived and designed the experiments; KQ, WL, SW, XW, TK, ZW and YW analyzed the data; CL performed the experiments; KQ, WL, SW, XW, TK, ZW and YL revised the manuscript. All authors have read and approved the manuscript.

Funding

This work was supported by National Natural Science Foundation of China (NSFC) Grant 81771147 and 81971019 to YW (design of the study, conduction of the experiments, analysis, interpretation of data and writing the manuscript), Grant 81870832 to ZW (conduction of the experiments, analysis, interpretation of data), National Natural Science Foundation of Shandong Province of China ZR2016HM30 to YW (design of the study, conduction of the experiments, analysis, interpretation of data and writing the manuscript) and Science and Technology Bureau of Jining City Grant 2017SMNS006 to SW(conduction of the experiments, analysis, interpretation of data and writing the manuscript).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.
Competing interests
The authors declare that they have no competing interests.

Author details
1Cheeloo College of Medicine, Shandong University, 44 Wenhua West Road, Liaodong District, Jinan, Shandong, China. 2Shandong Collaborative Innovation Center for Diagnosis, Treatment and Behavioral Interventions of mental disorders, Institute of Mental Health, Jining Medical University, 133 Hehua Road, Taibaihu New District, Jining, Shandong, China. 3Shandong Key Laboratory of Behavioral Medicine, School of Mental Health, Jining Medical University, 133 Hehua Road, Taibaihu New District, Jining, Shandong, China. 4The National Clinical Research Center for Geriatric Disease, Xuanwu Hospital, Capital Medical University, Beijing, China. 5Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.

Received: 6 December 2019 Accepted: 5 March 2020
Published online: 11 March 2020

References
1. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984;122(3):1131–5.
2. Wang X, Zhou X, Li G, Zhang Y, Wu Y, Song W. Modifications and trafficking of APP in the pathogenesis of Alzheimer's disease. Front Mol Neurosci. 2017;10:294.
3. Sun X, He G, Song W. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. Official Publication Fed Am Soc Exp Biol. 2006;20(9):1369–76.
4. Yan R. Physiological functions of the beta-site amyloid precursor protein cleaving enzyme 1 and 2. Front Mol Neurosci. 2017;10:97.
5. Liu F, Zhang Y, Liang Z, Sun Q, Liu H, Zhao J, Xu J, Zheng J, Yun Y, Yu X, et al. Cleavage of potassium channel Kv2.1 by BACE2 reduces neuronal apoptosis. Mol Psychiatry. 2018;23(7):1542–54.
6. Wang Z, Xu Q, Cai F, Liu X, Wu Y, Song W. BACE2, a conditional beta-secretase, contributes to Alzheimer's disease pathogenesis. JCI Insight. 2019; 4(11):123431.
7. Holler CJ, Webb RL, Laux AL, Beckett TL, Niedowicz DM, Ahmed RR, Liu Y, Simmons CR, Dowling AL, Spinelli A, et al. BACE2 expression increases in human neurodegenerative disease. Am J Pathol. 2012;180(1):337–50.
8. Myllykangas L, Wavrant-De Vrieze F, Polvikoski T, Notkola IL, Sulkava R, Niinisto L, Elandd SD, Arepalli S, Adighibe O, et al. Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study. J Neurol Sci. 2005;236(1–2):17–24.
9. Mok KY, Jones EL, Hanney M, Harold D, Sims R, Williams J, Ballard C, Hardy J. Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. Neurobiol Aging. 2014;35(8):1513 e1511–5.
10. Huentelman M, De Both M, Jepsen W, Piras B, Talboom JS, Willermen M, Reiman EM, Hardy J. Common BACE2 polymorphisms are associated with altered risk for Alzheimer's disease and CSF amyloid biomarkers in APOE epsilon4 non-carriers. Sci Rep. 2019;9(1):9640.
11. Acquati F, Accarino M, Nucci C, Fumagalli P, Jovine L, Ottoleghi S, Taramelli R. The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett. 2000;488(1):59–64.
12. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998; 67:425–79.
13. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005;6(1):79–87.
14. Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y. The role of ubiquitin proteasomal system and autophagy-lysosome pathway in Alzheimer's disease. Rev Neurosci. 2017;28(8):861–8.
15. Whiffin AJ. The production, assay, and antibiotic activity of actidioline, an antibiotic from Streptomyces griseus. J Bacteriol. 1948;56(3):283–91.
16. Wu Y, Song W. Regulation of RCAN1 translation and its role in oxidative stress-induced apoptosis. FASEB J. Official Publication Fed Am Soc Exp Biol. 2013;27(1):208–21.
17. Liu S, Bromley-Brits K, Xia K, Mittelholz J, Wang R, Song W. TMP21 degradation is mediated by the ubiquitin-proteasome pathway. Eur J Neurosci. 2008;28(10):1980–8.
18. Liu X, Wang Z, Wu Y, Wang J, Song W. BACE2 degradation mediated by the macroautophagy-lysosome pathway. Eur J Neurosci. 2013;37(2):1970–7.